Related by context. All words. (Click for frequent words.) 79 #mg BID [001] 71 mcg QD 71 #mg QD [002] 71 LPV r 71 PREZISTA r 70 weekly subcutaneous injections 70 urate lowering therapy 70 ABC/3TC 70 interferon ribavirin 70 CIMZIA TM certolizumab pegol 69 mg QD 69 TDF FTC 69 mcg BID 69 clodronate 69 ribavirin RBV 69 CIMZIA TM 69 mcg Albuferon 69 HCV RESPOND 2 69 randomized #:#:# 68 atazanavir ritonavir 68 lopinavir r 68 dose cohort 68 octreotide LAR 68 darunavir r 68 achieved ACR# 68 mg kg dose 68 LEXIVA r 68 weekly intravenous infusions 68 4mg/kg 68 comparator arm 68 #mg/m# [002] 67 Peg IFN 67 BARACLUDE ® 67 piperacillin tazobactam 67 alfa 2a 67 #mg/day [001] 67 ATACAND 67 tipranavir r 67 lopinavir r arm 67 mitoxantrone plus 67 q#h 67 virologic failure 67 mg BID 67 desvenlafaxine succinate 67 plus 5-FU/LV 67 subcutaneous enoxaparin 67 ritonavir boosted 67 #mg/day [002] 67 dalteparin 66 daily subcutaneous injections 66 pegylated interferon peg IFN 66 #mg BID [003] 66 active comparator 66 PEG IFN 66 REYATAZ r 66 oral rivaroxaban 66 ACTEMRA TM 66 chemoradiation therapy 66 plus methotrexate 66 detectable HCV RNA 66 #mg ATC 66 intermittent dosing 66 dose regimens 66 RLAI 66 dosing cohorts 66 APTIVUS r 66 mg TID 66 abacavir lamivudine 66 sustained virologic response 66 rapid virologic response 66 adalimumab Humira 66 saline placebo 66 prior chemotherapy regimens 66 telaprevir dosing 66 peginterferon alfa 2b 65 placebo p = 65 flutamide 65 elevated transaminases 65 mg ustekinumab 65 mg qd 65 recurrent glioblastoma multiforme 65 placebo dexamethasone 65 salmeterol fluticasone 65 morphometric vertebral fractures 65 genotypic resistance 65 tenofovir emtricitabine 65 amoxicillin clavulanate 65 GnRH agonist 65 antiretroviral naïve 65 β blockers 65 % CI #.#-#.# [003] 65 pegylated interferon alfa 2b 65 elagolix 65 zolmitriptan 65 peg interferon 65 FOLFOX4 65 ibandronate 65 treatment naive genotype 65 nicardipine 65 efavirenz EFV 65 administered subcutaneously 65 NATRECOR R 65 QTcF 65 carboplatin paclitaxel 65 mcg kg 65 docetaxel chemotherapy 65 antiretroviral naive 64 neurologic progression 64 8mg/kg 64 ug dose 64 q8h 64 mg administered orally 64 clevidipine 64 corticosteroid dose 64 #mg doses [002] 64 relapsed CLL 64 tolterodine ER 64 BEACOPP 64 relapsed MM 64 FOLFIRI 64 plus prednisone 64 atorvastatin #mg 64 anthracyclines taxanes 64 mapatumumab 64 postmenopausal osteoporotic women 64 timepoint 64 β blocker 64 unfractionated heparin UFH 64 Tarceva TM 64 mRCC 64 lamivudine monotherapy 64 irbesartan 64 peginterferon 64 PREZISTA ritonavir 64 peginterferon alfa 2a 64 #mg dosing 64 AZT zidovudine Retrovir 64 VELCADE melphalan 64 R entecavir 64 mg subcutaneously 64 pegylated interferon alpha 64 BoNTA 64 subcutaneous injections 64 pegaptanib 64 mcg albinterferon alfa 2b 64 adjunctive placebo 64 anagrelide 64 IFN alfa 64 FOLFIRI alone 64 p = NS 64 evaluable subjects 64 rFVIIa 64 #mg/m# [001] 64 Fludara 64 nadolol 64 ribavirin therapy 64 DAPT 64 injected subcutaneously 64 ORENCIA ® 63 achieved statistical significance 63 FOLFOX6 63 doxorubicin docetaxel 63 undetectable HCV RNA 63 subcutaneously administered 63 oral antidiabetic medication 63 ascending dose 63 oxycodone CR 63 Elitek 63 noninferior 63 Pegasys plus Copegus 63 dosed orally 63 certolizumab 63 progression TTP 63 mg RDEA# 63 prucalopride 63 levosimendan 63 tolvaptan 63 severe neutropenia 63 paricalcitol 63 RGT arm 63 virological failure 63 mg/m2 dose 63 #mg dose [002] 63 mitoxantrone 63 insulin detemir 63 5-FU/LV 63 Folfox 63 intradermal injections 63 PEGINTRON TM 63 biphasic insulin aspart 63 HBeAg negative patients 63 Xelox 63 unresectable HCC 63 mg/m2 IV 63 oral diclofenac 63 methotrexate therapy 63 Helicobacter pylori eradication 63 FOLFOX 63 clomipramine 63 adalimumab 63 divalproex sodium 63 plus ribavirin 63 stage IIIb IV 63 bleeding pallor 63 de novo kidney transplant 63 ascending doses 63 leuprorelin 63 mcg doses 63 peginterferon alpha 2a 63 nab paclitaxel 63 adefovir treated 63 ALVESCO 63 otamixaban 63 NATRECOR ® 63 deep venous thromboses 63 mg m² 63 Virologic 63 maximal doses 63 telaprevir dosed 63 naïve HCV 63 low dose cytarabine 63 interferon alfa 2a 62 achieved PASI 62 #mg dose [003] 62 mg/# hr 62 cisplatin vinorelbine 62 undetectable virus HCV 62 peg IFN 62 mesalamine granules 62 zonisamide SR 62 insulin glulisine 62 forodesine 62 anthracycline taxane 62 mg/m2 administered 62 eosinophilic asthma 62 QD dosing 62 INFERGEN 62 adefovir 62 FOLFOX4 alone 62 5mg/kg 62 pegylated interferon alpha 2a 62 undetectable HBV DNA 62 corifollitropin alfa 62 intravenous iv 62 microgram kg 62 FROVA 62 null responder HCV 62 Doxil ® 62 docetaxel Taxotere ® 62 anthracycline chemotherapy 62 #mg/kg [002] 62 dose titration 62 CANCIDAS 62 mg dose 62 virologically 62 ritonavir boosted lopinavir 62 CCyR 62 metastatic HRPC 62 treatment naïve genotype 62 mcg dose 62 ARCOXIA 62 estramustine 62 PRADAXA #mg 62 candesartan cilexetil 62 taxane resistant 62 bicifadine 62 riociguat 62 FOLPI 62 ancrod 62 receiving prophylactic anticoagulation 62 RRMS patients 62 mg eq 62 fluticasone salmeterol 62 NRTI 62 IOP lowering 62 lenalidomide Revlimid R 62 dose dexamethasone 62 immunomodulatory therapy 62 ULORIC 62 n = 62 nadroparin 62 dosage regimens 62 unfractionated heparin 62 metformin monotherapy 62 steroid dexamethasone 62 CIMZIA ™ 62 μg kg 62 dapagliflozin plus 62 ARB telmisartan 62 bolus injection 62 mg q#h 62 dexmedetomidine 62 NLX P# 62 RSD# oral 62 Decompensated Heart Failure 62 tirofiban 62 nonmetastatic prostate cancer 62 virologic breakthrough 62 infliximab monotherapy 62 ZOLINZA 62 SVR# 62 mg orally 62 Viread Emtriva 62 MULTAQ 62 #.#g/day 62 recurrent malignant glioma 62 dose cohorts 62 hour bronchodilation 62 CLARITY study 62 mg/m2/day 62 dose cyclophosphamide 62 cilengitide 62 infliximab 62 dacarbazine 62 monotherapy 62 pegylated interferon alfa 2a 62 Nebulized 62 plus dexamethasone 62 doxorubicin cyclophosphamide 62 median PFS 62 tacrolimus ointment 62 aflibercept VEGF Trap 62 solifenacin 62 lanthanum carbonate 62 mg d 62 mg FV 62 tipranavir ritonavir 62 rhGH 62 generalized edema 62 relapsing remitting MS RRMS 62 pentoxifylline 62 Pivotal Phase III 62 nelfinavir 62 systemic hypotension 61 seroconverted 61 paclitaxel carboplatin 61 CLL SLL 61 receiving highly emetogenic 61 undetectable viral 61 baminercept 61 ARCALYST ® 61 non splenectomized 61 protease inhibitor PI 61 dexamethasone Decadron 61 mCi kg 61 Adjunctive 61 voriconazole 61 sorafenib Nexavar 61 dosing cohort 61 Free Survival PFS 61 low dose Iluvien 61 achieved CCyR 61 sitaxsentan 61 timepoints 61 PREZISTA rtv 61 sorafenib tablets 61 imatinib therapy 61 Pegasys ® 61 assessing T DM1 61 ug kg 61 rFSH 61 motesanib 61 TMP SMX 61 bosentan 61 IV bolus 61 primary hypercholesterolemia 61 mg doses 61 biochemical relapse 61 NNRTI resistance 61 CIMZIA R 61 VIRAMUNE 61 concomitant medications 61 receiving VICTRELIS 61 aromatase inhibitor therapy 61 KRAS mutations occur 61 Patency 61 GOUT 61 tenecteplase 61 PROMACTA 61 valacyclovir 61 Pegylated Interferon 61 subcutaneous insulin 61 CK # administered 61 metastatic malignant melanoma 61 DOXIL 61 Median PFS 61 venlafaxine XR 61 amprenavir 61 intravenous vancomycin 61 ertapenem 61 SPRYCEL ® 61 cetuximab Erbitux R 61 prospectively defined 61 paclitaxel eluting stents 61 MAS XR 61 colorectal cancer liver metastases 61 HIV RNA 61 deferoxamine 61 multicenter Phase II 61 HCV SPRINT 61 ceftazidime 61 ß blockers 61 nucleoside naive 61 pamidronate 61 metastatic GIST 61 Aptivus ® 61 diabetic neuropathic pain 61 3mg/kg 61 log# IU mL 61 μg dose 61 cilostazol 61 oral allopurinol 61 overt nephropathy 61 Pemetrexed 61 EUFLEXXA R 61 postprocedure 61 alefacept 61 tenofovir FTC 61 bone marrow reticulin deposition 61 Dose escalation 61 tapentadol ER 61 subcutaneous doses 61 Teriflunomide 61 aprepitant 61 #:# randomization 61 ciclesonide 61 phase IIIb 61 ACR# response 61 glycoprotein IIb IIIa inhibitor 61 HBeAg positive patients 61 PASI scores 61 alpha 2a 61 sustained virological response 61 phase IIb clinical 61 mg/m2 61 antithymocyte globulin 61 fosbretabulin 61 complete cytogenetic response 61 mg p = 61 reduce serum phosphate 61 dose escalation clinical 61 REMICADE ® 61 tipranavir 61 celgosivir 61 interferon alfa 2b 61 viral kinetics 61 ® lenalidomide 61 adjuvant cisplatin 61 Phase Ib clinical 61 galiximab 61 sunitinib 61 Triapine R 61 etanercept 61 olmesartan 61 mycophenolate mofetil 61 evaluable 61 AEGR 61 entecavir 61 acute coronary syndromes ACS 61 Vidaza azacitidine 61 teriflunomide 61 plasma uric acid 61 INVEGA ® 61 basal bolus regimen 61 trimethoprim sulfamethoxazole 60 budesonide pMDI 60 methylprednisolone 60 Viread Emtriva Sustiva 60 transaminase elevations 60 symptomatic intracranial 60 CI -#.# 60 placebo p 60 postoperative chemotherapy 60 GSK# [001] 60 #/#mg 60 receiving PEGINTRON 60 oral levofloxacin 60 methotrexate monotherapy 60 ritonavir boosted protease inhibitor 60 Capesaris 60 abatacept 60 genotype 1b 60 Median survival 60 non inferiority 60 oxymorphone ER 60 placebo 60 CHOP chemotherapy 60 achieved mucosal healing 60 P = .# 60 aripiprazole Abilify 60 PSA nadir 60 liposome injection 60 infusional 5-FU/LV 60 placebo intravenously 60 -#.# log# 60 achieved sustained virological 60 fluoropyrimidine 60 remission CR 60 binary restenosis 60 MIRAPEX 60 nilotinib 60 pharmacokinetic parameters 60 blinded randomized placebo controlled 60 COZAAR 60 systolic dysfunction 60 virological response 60 QT QTc 60 analgesic efficacy 60 FUSILEV enhances 60 intravitreal insert 60 evaluating tivozanib 60 argatroban 60 Sapacitabine 60 titrated glipizide 60 docetaxel prednisone 60 PEGASYS ® 60 Sprycel dasatinib 60 plus prednisone prednisolone 60 pegylated liposomal doxorubicin 60 paclitaxel cisplatin 60 Engerix B 60 idursulfase 60 taxotere 60 golimumab CNTO 60 clazosentan 60 TNF antagonist 60 rimonabant #mg 60 oral prednisone 60 postintervention 60 CHAMPION PCI 60 vandetanib 60 corticosteroid therapy 60 double blinded placebo 60 dose cytarabine 60 experienced virologic failure 60 colesevelam HCl 60 hypokalemia 60 MAGE A3 ASCI 60 lintuzumab SGN 60 recurrent VTE 60 TO AVOID PREGNANCY WHILE 60 MGd 60 IV tPA 60 hours postdose 60 degarelix 60 REMINYL ® 60 ropivacaine 60 LMWH 60 primary patency 60 peginterferon alfa 2a Pegasys 60 comparator PI r 60 intravenous cyclophosphamide 60 intravenous diuretics 60 pegylated interferon 60 tamsulosin 60 azilsartan medoxomil 60 rt PA 60 trastuzumab Herceptin ® 60 metformin hydrochloride 60 symptomatic BPH 60 telaprevir VX 60 HBeAg negative 60 intravitreal injection 60 alfa 2b 60 lipid lowering agents 60 goserelin 60 5 Fluorouracil 60 Paxil paroxetine 60 apremilast 60 acutely decompensated congestive heart 60 BRIM2 60 underwent liver transplantation 60 macrolide antibiotic 60 lenalidomide dexamethasone 60 acute STEMI 60 idraparinux 60 mg simvastatin 60 fatigue asthenia 60 visilizumab 60 Acute Ischemic Stroke 60 EGFR TKI 60 remission induction 60 cetuximab Erbitux ® 60 antiarrhythmic drug 60 relapsing multiple sclerosis 60 AIR CF1 60 platelet inhibitor 60 ziprasidone 60 COMBIVIR 60 spontaneous bowel movements 60 ZACTIMA 60 statin monotherapy 60 gemcitabine carboplatin 60 placebo controlled clinical trials 60 intravenous bolus 60 Tolvaptan 60 either acutely decompensated 60 infliximab therapy 60 microbiologically evaluable 60 Hazard Ratio = 60 seropositive patients 60 interferon gamma 1b 60 metastatic colorectal carcinoma 60 TPV r 60 chlorambucil 60 mCi 60 DU #b 60 % CI #.#-#.# [007] 60 phase Ib 60 Copegus ribavirin 60 cinacalcet 60 response CCyR 60 urate lowering 60 lispro 60 Q2W 60 prospectively enrolled 60 phase IIa 60 acute gout flares 60 thromboprophylaxis 60 CAELYX 60 anthracycline therapy 60 refractory AML 60 BENICAR HCT 60 glatiramer acetate 60 invasive aspergillosis 60 retinal vein occlusion induced 60 underwent surgical resection 60 pooled comparator 60 BARACLUDE R 60 3TC lamivudine Epivir 60 esophageal candidiasis 60 refractory CLL 60 nonvertebral fractures 60 Lipitor #mg 60 #μg [002] 60 Raptiva r 60 irinotecan containing 60 CALGB # [002] 60 budesonide foam 60 Kinoid 60 chemoradiotherapy 60 fosamprenavir 60 bolus dose 60 adriamycin 60 splenectomized 60 Contrave# 60 unstable angina UA 60 FTC TDF 60 docetaxel pretreated 60 decitabine 60 smoldering multiple myeloma 60 INTEGRILIN R 60 ribavirin USP 60 cisplatin chemotherapy 60 brivaracetam 60 serum phosphorous 60 clopidogrel Plavix 60 HBeAg seroconversion 60 1mg 2mg 60 inhibitor RG# 60 eptifibatide 60 milliliters mL 60 thromboembolic events 60 PegIntron 60 Capecitabine 60 achieved sustained virologic 60 ELACYT 60 MMX mesalamine 60 alpha interferons 60 ONGLYZA saxagliptin 60 Aflibercept 60 FluCAM arm 60 fallopian tube cancers 60 Postoperatively 60 stage IIIB 60 treprostinil 60 antiandrogen 60 mcg kg REBETOL 60 Cimzia TM 59 icatibant 59 MYCAMINE 59 maximally tolerated dose 59 investigational protease inhibitor 59 gout flares 59 acetazolamide 59 dual antiplatelet 59 VEGF receptor inhibitor 59 ritonavir boosted atazanavir 59 TLUS 59 recurrent metastatic 59 placebo controlled Phase 59 rosuvastatin #mg 59 trials RCTs 59 elotuzumab 59 fostamatinib 59 leukemia AML 59 MBq 59 androgen deprivation 59 omega interferon 59 ezetimibe simvastatin 59 reteplase 59 OADs 59 definite stent thrombosis 59 aspartate aminotransferase 59 concomitant antibiotics 59 peginterferon alfa 59 noninferiority 59 #mg BID [002] 59 mcg kg min 59 melphalan prednisone 59 intramuscularly 59 chronic HCV genotype 59 Betaferon R 59 androgen suppression 59 metastatic castration resistant 59 metastatic CRC 59 administered intradermally 59 zalutumumab 59 relapsed refractory multiple myeloma 59 alteplase 59 adjunctive ABILIFY 59 statistically significant p = 59 DMARD therapy 59 Myelodysplastic Syndrome MDS 59 nitazoxanide 59 debulking surgery 59 elevated ALT 59 R adefovir dipivoxil 59 TMC# C# 59 VAPRISOL 59 pyridostigmine 59 tolterodine 59 plus COPEGUS 59 Thal Dex 59 vicriviroc 59 visceral metastases 59 nevirapine Viramune 59 refractory chronic lymphocytic 59 randomized Phase IIb 59 mg hydrochlorothiazide 59 ethambutol 59 SSRI citalopram 59 Kivexa 59 Telithromycin 59 oral anticoagulant therapy 59 cediranib 59 Pegylated Liposomal Doxorubicin 59 gastrointestinal perforation 59 acromegalic patients 59 ACE inhibitor ramipril 59 SomatoKine R 59 thienopyridines 59 caspofungin 59 HbA1c levels 59 VFEND 59 dual endothelin receptor antagonist 59 plus MTX 59 antiepileptics 59 unresectable stage 59 pyrazinamide 59 cisplatin gemcitabine 59 oral vancomycin 59 taxane chemotherapy 59 myelodysplastic myeloproliferative diseases 59 clinically meaningful improvement 59 lumiliximab 59 PegIFN RBV 59 pain palliation 59 phase IIb study 59 Abrupt discontinuation 59 ExTRACT TIMI 59 diuretic chlorthalidone 59 fluticasone propionate 59 Traficet EN 59 CTEPH 59 paroxysmal AF 59 TNF inhibitor 59 Noxafil 59 fluorouracil leucovorin 59 headache nasopharyngitis 59 posttransplant 59 BR.# 59 Zometa hazard 59 rilpivirine 59 PEGylated interferon beta 1a 59 systemic ALCL 59 plus OBT 59 placebo controlled clinical 59 TMC# r 59 virologic response 59 metastatic malignant 59 antibody MAb 59 hypomagnesemia 59 anastrazole 59 levetiracetam 59 daily Infergen 59 hematologic toxicity 59 milrinone 59 GAMMAGARD 59 ELOXATIN 59 oral antidiabetic agents 59 salmeterol fluticasone propionate 59 treatment naļve 59 detemir 59 etanercept Enbrel 59 abiraterone acetate 59 Femara letrozole 59 CR nPR 59 Lubiprostone 59 COU AA 59 clotrimazole 59 STRIDE PD 59 perioperatively 59 standard chemotherapy regimen 59 oral ridaforolimus 59 idarubicin 59 μmol L 59 multicenter Phase III 59 aldosterone antagonist 59 Ozarelix 59 Acetate Rectal Suppositories 59 intravesical 59 #mg #mg #mg [003] 59 iniparib 59 DMARD 59 AGILECT R 59 TORISEL 59 IFN α 59 PEGylated anti 59 mg subcutaneous 59 peginterferon alfa 2a #KD 59 subcutaneous SC 59 TYGACIL 59 underwent percutaneous coronary 59 zoledronate 59 biliary tract cancer 59 administered intranasally 59 interquartile range 59 copies mL 59 intra articular injection 59 glufosfamide 59 thorough QT 59 posaconazole 59 REVLIMID lenalidomide 59 IIIa inhibitor 59 confidence interval CI 59 HGS ETR1 mapatumumab 59 NMIBC 59 phase IIb trial 59 aminotransferase elevations greater 59 Flu Cy 59 Amrubicin 59 posttreatment 59 Oropharyngeal Candidiasis 59 somatostatin analog 59 Primary endpoints 59 Pharmacokinetics PK 59 APTIVUS 59 mycophenolate mofetil MMF 59 TMC# [001] 59 log# reduction 59 epoetin alpha 59 intravitreal injections 59 COPD exacerbation 59 placebo controlled Phase III 59 lanreotide 59 azathioprine 59 TAXOTERE R 59 oral methylnaltrexone 59 benazepril 59 Ixempra 59 infusional 59 hypophosphatemia 59 bupropion SR 59 cefazolin 59 Phase 1a clinical 59 edifoligide 59 PEG interferon 59 secondary efficacy endpoints 59 INSPIRE Trial Phase III 59 microgram mcg 59 multicenter Phase 59 GP IIb IIIa inhibitors 59 aldosterone antagonists 59 Meets Primary Endpoint 59 rizatriptan 59 aspartate aminotransferase AST 59 receiving INTRON 59 febrile neutropenia 59 SCH # 59 alanine aminotransferase ALT 59 darunavir ritonavir 59 plus gemcitabine 59 REYATAZ ritonavir 59 Interferon beta 1b 59 safinamide 59 HAART regimens 59 reinfarction 59 Mitoxantrone 59 M#V mutation 59 flecainide 59 mitoxantrone chemotherapy 59 copies ml 59 virus HCV infection 59 triptorelin 59 Dacogen injection 59 lapatinib Tykerb 59 continuous intravenous infusion 59 refractory CTCL 59 angiotensin converting enzyme inhibitor 59 molindone 59 Cloretazine 59 darbepoetin alfa 59 clobazam 59 Natalizumab 59 intravenous REOLYSIN 59 pomalidomide 59 5FU 59 aspirin clopidogrel 59 Thrombolysis 59 CRp 59 aflibercept 59 Randomized Phase 59 resected pancreatic cancer 59 randomized blinded 59 mg kg IV 59 REBETOL 59 miconazole 59 adjuvant colon cancer 58 #mg/#mg 58 p = #.# [004] 58 certolizumab pegol 58 prospectively evaluated 58 doxorubicin HCl liposome injection 58 cyclophosphamide doxorubicin vincristine 58 antimicrobial prophylaxis 58 Newly Diagnosed Multiple Myeloma 58 chronic GVHD 58 atazanavir sulfate 58 demonstrated antitumor activity 58 CYPHER Stent 58 eculizumab therapy 58 fluvastatin 58 RoACTEMRA 58 XIENCE V PROMUS Stent 58 prespecified 58 Oral Fingolimod 58 valsartan amlodipine 58 PegIFN 58 adenoma recurrence 58 EURIDIS 58 dosing intervals 58 INCB# [003] 58 mg tid 58 odanacatib 58 pioglitazone 58 timolol 58 IFN beta 58 REYATAZ r arm 58 cytopenias 58 #Gy 58 Irinotecan 58 valopicitabine 58 pioglitazone HCl 58 nevirapine NVP 58 q#d 58 6 mercaptopurine 58 biologic DMARD 58 Patients Receiving 58 KRAS mutant tumors 58 Kaplan Meier analysis 58 cis retinoic acid 58 interferon beta 1a 58 EXJADE 58 Median progression 58 multicenter randomized placebo controlled 58 xanthine oxidase inhibitor 58 QTc 58 REYATAZ R 58 ara C 58 receptor tyrosine kinase inhibitor 58 oral deforolimus 58 mg dosed twice 58 vapreotide acetate 58 TRIZIVIR 58 EVIZON 58 paroxetine Paxil 58 LATUDA 58 catheter occlusion 58 insulin degludec 58 cerebrovascular events 58 HIV HCV coinfected 58 Peginterferon 58 metastatic hormone refractory 58 refractory NSCLC 58 Decitabine 58 acutely decompensated heart 58 octreotide acetate 58 pegylated liposomal doxorubicin PLD